Close Menu

Quanterix

The company posted Q4 revenues of $26.1 million, up from $15.9 million in Q4 2019, and beat the consensus Wall Street estimate of $23.4 million.

News items for the in vitro diagnostics industry for the week of Feb. 8, 2021.

The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.

Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.

The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.

The company's automated immunoassay is designed to qualitatively detect the SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swab specimens.

The EUA for the antibody test follows funding that Quanterix received recently from BARDA for the development of a SARS-CoV-2 antigen test.

For the three months ended Sept. 30, the Billerica, Massachusetts-based company posted Q3 revenues of $31.4 million, up from $14.9 million in Q3 2019.

The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.

Pages